Cutaneous melanoma is predominantly a disease of fair-skinned individuals. Risk factors include a family history^[@R1]^, certain pigmentation phenotypes (notably the presence of fair skin, blue or green eyes, blond or red hair, sun sensitivity or an inability to tan^[@R2]-[@R5]^) and increased numbers of melanocytic nevi^[@R6],[@R7]^. We previously reported Phase 1 of a genome-wide association (GWA) study of melanoma based on the Illumina 317k array^[@R8]^. This reinforced the importance of these genetically-determined melanoma-associated phenotypes, by showing the major common genetic determinants of risk in the populations considered were the *MC1R* locus (associated with red hair, freckling and sun sensitivity)^[@R4],[@R5],[@R9],[@R10]^, tyrosinase (*TYR*) gene variants which code for skin color^[@R11]^ and a region near *CDKN2A* and *MTAP* which is associated with number of melanocytic nevi^[@R8],[@R12]^. Furthermore we confirmed the importance of a haplotype spanning the agouti signaling protein locus (*ASIP*)^[@R11],[@R13]^ and a second locus determining nevus count variation at 22q13 identified by a GWA study of nevus count^[@R12]^.

Both Phase 1 and Phase 2 of this study were carried out by the GenoMEL Consortium, a collaboration focusing on genetic susceptibility to melanoma. The study utilised samples collected by GenoMEL participants across populations of European ancestry living at different latitudes. In total, 14 GenoMEL groups contributed DNA samples from cases and controls of European (or Israeli) ethnicity ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Phase 1 was based on 1,650 cases from Australian and European populations chosen to have a phenotype argued to "enrich" for genetic susceptibility (early onset, multiple primaries, or modest family history of melanoma). In Phase 2 a further 1,523 cases (1,211 of whom are genetically enriched: 532 with a family history, 277 with multiple primaries but no family history, and 402 with early disease onset but no multiple primaries or family history) and 1,112 controls were genotyped using the denser Illumina 610k array (see [Supplementary Note](#SD1){ref-type="supplementary-material"}). To optimise power for novel gene identification we combined the data from the two phases and performed an overall analysis. The Australian data used in Phase 1 were dropped from the combined Phase 1 + Phase 2 analysis as these samples are included in the Australian GWA study which formed one of the replication studies. After quality control was applied to SNPs and samples (see [Supplementary Note](#SD1){ref-type="supplementary-material"}), including Principal Components Analysis (PCA) to identify samples of non-European ethnicity ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), the analysis utilised 2,804 cases (2,692 European and 112 Israeli) and 1,835 controls from GenoMEL studies and 5,783 controls from France and the UK Wellcome Trust Case-Control Consortium (WTCCC). A trend test, stratified by geographical region, was applied to each SNP (see Online Methods, also [Figure 1](#F1){ref-type="fig"}). Little evidence was found of population stratification (*λ*=1.06, see [Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

Strong evidence was found for the previously identified loci, ([Supplementary Table 2, Supplementary Figures 2 and 3](#SD1){ref-type="supplementary-material"})^[@R8],[@R11]-[@R18]^ and another pigmentation gene, *SLC45A2*, already reported to be associated with melanoma risk^[@R15]^. *SLC45A2* is involved in melanosome maturation and pigmentation. The rs35390 SNP identified here is associated with melanoma^[@R15]^ and with variation in hair color^[@R15],[@R20]^, in accordance with the observed pattern of known melanoma pigmentation risk factors^[@R2]-[@R5]^.

We also confirmed a role for SNP rs401681 in the region of *TERT* and *CLMPT1L*, which has also previously been shown to modify melanoma risk^[@R18]^ ([Supplementary Table 2, Supplementary Figures 2 and 3](#SD1){ref-type="supplementary-material"})^[@R8],[@R11]-[@R16],[@R21]^. The confirmation of the SNP follows reported associations with risk of basal cell carcinomas, hematological malignancies and cancer of the bladder, cervix, lung, pancreas and prostate^[@R18],[@R22]^. It was originally reported that the pattern of risk for melanoma was in the opposite direction to that for other cancers^[@R18]^, and we confirm this observation.

Seven further regions showed evidence of association with melanoma susceptibility ([Table 1](#T1){ref-type="table"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Replication was sought from two other GWA studies for the SNPs with the strongest evidence, preferentially SNPs common to all arrays. In regions with no SNP common to all platforms, we followed up both our top genotyped SNPs and the most significant imputed SNPs which had been genotyped in the replication studies. Further, these SNPs were genotyped in a replication sample set from the UK and the Netherlands (1,579 cases and 2,036 controls in total, see [Supplementary Note](#SD1){ref-type="supplementary-material"}). [Table 1](#T1){ref-type="table"} contains the evidence from both the hypothesis-generating and replication datasets. Of these seven regions, three (on chromosomes 2 (rs13016963), 11 (rs1801516) and 21) showed strong evidence of replication (p\<10^−3^), three (on chromosomes 2 (rs10932444), 12 and 13) showed no evidence of replication and one (on chromosome 11 (rs1485993)) showed marginal evidence of replication. Three of the loci showed overall combined evidence of association at p\<5×10^−8^, based on the fixed effects meta-analysis.

The *CASP8* region (chromosome 2) contains a number of SNPs showing evidence for association with melanoma risk; because of the lack of overlap in the SNPs across arrays, we report multiple SNPs either genotyped or imputed across platforms, all of which show evidence of association ([Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SD1){ref-type="supplementary-material"}, [Figure 2](#F2){ref-type="fig"}). The strongest evidence for a single SNP is for rs700635 (p=2.4×10^−9^, OR=1.15 overall). All the SNPs are in the region of *CASP8*, which codes for a member of a family of proteases that play a critical role in the control of cell proliferation by inducing apoptotic cell death, making them candidate cancer susceptibility genes. A recent meta-analysis^[@R23]^ of 3 polymorphisms in *CASP8* found that individuals with one or more copies of the D302H variant have a decreased risk of multiple types of cancer. In this study, the D302H variant could be imputed, but showed only marginal evidence of association (p=0.05), suggesting this is not a variant for melanoma. The evidence for melanoma risk was consistent across populations ([Figure 3](#F3){ref-type="fig"}).

The *ATM* SNP rs1801516 (chromosome 11) ([Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SD1){ref-type="supplementary-material"}, [Figure 2](#F2){ref-type="fig"}) is a missense mutation (D1853N, G \> A) in a gene that codes for a protein which repairs double strand DNA breaks; association has been postulated between *ATM* and a number of cancer types^[@R24]^. For melanoma, the A allele is protective (p=3.4×10^−9^, OR=0.84 overall). Overall the evidence for melanoma is consistent across populations and case type, with no evidence of heterogeneity ([Figure 3](#F3){ref-type="fig"}).

The third replicated region, around *MX2* (chromosome 21), showed consistent effect sizes across the replication datasets ([Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SD1){ref-type="supplementary-material"}, [Figure 2](#F2){ref-type="fig"}) and across populations ([Figure 3](#F3){ref-type="fig"}). The SNP followed up in the replication study is rs45430 (p=2.9×10^−9^, OR=0.88 overall), which is intronic to *MX2* and has not previously been associated with cancer susceptibility.

A fourth region, adjacent to *CCND1* (chromosome 11), a proto-oncogene which is a key regulator of cell cycle progression, showed consistent effect sizes across all the replication sets ([Table 1](#T1){ref-type="table"}, [Supplementary Table 3, Supplementary Figure 4](#SD1){ref-type="supplementary-material"}), with best overall replication p-value of 0.011. However the replication sets produced a notably smaller OR (1.08) than the discovery set (1.19) (I^2^=0.507). This is potentially due to the well known Winner\'s Curse effect^[@R25]^ that causes the initial discovery set to overestimate the OR, leading in turn to a discrepancy between the overall p-value based on fixed effects and random effects meta-analysis (p=1.7×10^−7^ and p=0.00046 respectively). Thus, while we have strong support from this region, the evidence cannot be considered conclusive (see [Supplementary Note](#SD1){ref-type="supplementary-material"} for further details). However, further support comes from the interim analysis of a recently completed melanoma GWA study in494 melanoma cases and 5,628 controls from the Nurses\' Health Study and Health Professionals Follow-up Study (OR=1.18 for rs1485993, p=0.014, unpublished data). This gene therefore remains a strong candidate, being well known in melanoma carcinogenesis^[@R26]^.

In Phase 1 of the study, all melanoma susceptibility loci identified were associated with either skin pigmentation or nevus count variation^[@R8]^. For the case-control samples from Leeds, UK, detailed nevus count and pigmentation information has been obtained for cases and controls^[@R27]^. [Table 2](#T2){ref-type="table"} shows the association between nevus count, pigmentation and all SNPs associated with melanoma. (Note that not all SNPs show convincing evidence of melanoma association within the Leeds case-control samples, reflecting limited power). As expected, *MC1R, SLC45A2, IRF4* and *TYR* are confirmed to be associated with pigmentation, while the rs4911442 SNP on chromosome 20 shows strong association with pigmentation, increasing the evidence that *ASIP* truly is the focus of this hit and implicating probable linkage disequilibrium (LD) with variants within an *ASIP* regulatory region. SNPs in the region of *CDKN2A/MTAP* and *PLA2G6* are associated with nevus variation. The *TERT/CLMPT1L* SNP is also associated with nevus count variation, suggesting its effect on melanoma risk modification may be via this mechanism. We previously showed that *IRF4* had a complex relationship with nevus count and melanoma risk^[@R14]^, and there are suggestions for SNPs in the *CASP8* region of a relationship between genotype and nevus count in controls; among cases the association is not apparent ([Table 2](#T2){ref-type="table"}). Finally, the SNPs in the *ATM* and *MX2* regions show no association with either nevus count or pigmentation, suggesting alternative, unknown mechanisms, although these require evaluation in other populations (see [Supplementary Note](#SD1){ref-type="supplementary-material"}).

Overall, we report 3 novel loci associated with melanoma risk, which achieve an overall significance level of 5×10^−8^ based on the fixed effects meta-analysis, and a potential fourth locus. The power to detect SNPs with effect sizes similar to those estimated from the replication studies is low, and we see many more SNPs in novel regions (from across the genome) reaching p-values between 10^−4^ and 10^−5^ than expected (68 with MAF\>0.05 compared with an expected 46), suggesting that there may be many other genetic regions with a similar effect on melanoma risk (see [Supplementary Note](#SD1){ref-type="supplementary-material"}). Currently 11 loci have been identified ([Table 2](#T2){ref-type="table"}), with a suggestion that 5 of these regions act through the pigmentation phenotype and at least 3 through the nevus phenotype, reflecting the major phenotype-associated risk factors for melanoma. Interestingly, at least two of the newly identified loci appear to influence risk through a novel mechanism, opening up potential new directions for melanoma research.
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![Manhattan plot of results of Cochran-Armitage (CA) trend test stratified by geographic region, with -log~10~ p-values shown. The solid horizontal line indicates a p-value of 10^−5^. Markers within 50kb of a SNP associated with melanoma are marked in black for those identified in a previous GWA and replicated here and marked in red if first identified in the current study. The y-axis is truncated at p=10^−15^, although three SNPs in the *MC1R* region have stronger p-values, up to 2.7×10^−27^, as signified by the box and arrow.](nihms335189f1){#F1}

![Stratified CA trend tests for the three replicated regions on chromosomes 2, 11 and 21. The log~10~ p-values are from the CA trend test (stratified by geographical region) for genotyped and imputed SNPs, indicated on the left-hand vertical axis. SNPs genotyped for all samples are plotted as circles, SNPs imputed for all samples as crosses and SNPs genotyped for some samples and imputed for others (due to chip differences) as squares. The most significant genotyped SNP is colored purple (with its name above) and the degree of LD between that SNP and the others is indicated by color according to the key (red being the greatest degree of LD). The estimated recombination rate is given by the blue line and indicated on the right-hand vertical axis. The genes in the region and their positions are given underneath the graph. Plots produced using LocusZoom^[@R19]^.](nihms335189f2){#F2}

![Forest plot of the per-allele OR for melanoma for SNPs in the 3 regions first identified in this study. Plots show the current evidence for effects by geography, in the genome-wide and replication samples, and by case type (family history, multiple primaries or early onset).](nihms335189f3){#F3}

###### 

Summary of results from this study for the 4 regions showing evidence of replication, listing each SNP under consideration, their position (in bp) and minor allele frequency (MAF); the per-allele OR (based on the minor allele) and p-value are given for this GWA study, for the meta-analysis of the replication data sets (from the Houston GWA study, the Australian GWA study and UK/Netherlands replication samples) and for the combined genome-wide and replication analyses. The Houston GWA study and the Australian study both used a different array to the current study for at least some samples, so some of their results presented here include imputed data. Further genotyping was conducted in the UK and Netherlands replication samples for SNPs with positive support from the GWA replication data. All meta-analyses are based on a fixed effects model with the exception of those for *CCND1*, marked with an asterisk, where random effects analysis was used because of the observed heterogeneity. [Supplementary Table 3](#SD1){ref-type="supplementary-material"} is a fuller version of this table.

  SNP          Chromosome   Position    Allele   MAF    GenoMEL Genome-wide   Replication samples (genotyped + imputed)   Genome-wide plus replication samples (genotyped + imputed)   Postulated gene                                                                       
  ------------ ------------ ----------- -------- ------ --------------------- ------------------------------------------- ------------------------------------------------------------ ----------------- --------------------------------------------------- --------------- -------
  rs13016963   2            201852173   A        0.37   1.18                  5.68 × 10^−7^                               1.11 (1.06, 1.18)                                            9.2 × 10^−5^      1.14 (1.09, 1.19)                                   8.6 × 10^−10^   CASP8
  rs1485993    11           69071595    A        0.37   1.19                  4.15 × 10^−7^                               1.07 (1.01, 1.13)                                            0.017             1.11 (1.04, 1.18)[\*](#TFN1){ref-type="table-fn"}   0.0012          CCND1
  rs1801516    11           107680672   A        0.13   0.79                  4.80 × 10^−7^                               0.87 (0.78, 0.90)                                            3.4 × 10^−4^      0.84 (0.78, 0.90)                                   3.4 × 10^−9^    ATM
  rs45430      21           41667951    G        0.39   0.85                  5.60 × 10^−7^                               0.91 (0.86, 0.96)                                            4.2 × 10^−4^      0.88 (0.85, 0.92)                                   2.9 × 10^−9^    MX2

Using random effects

###### 

Summary of results for nevus count/pigmentation/melanoma analyses from the Leeds case-control samples examining the 11 SNPs replicated for melanoma association in this or previous studies. Results are shown for (i) the proportion and significance of log nevus count variation explained by each SNP, adjusted for age and sex among cases and controls (adjusted for case-control status), (ii) the proportion and significance of case-control adjusted pigmentation variation score explained by each SNP, where the score is calculated from factor analysis of 6 correlated pigmentation phenotypes (see Online Methods), (iii) the association with melanoma risk (both as per-allele OR with 95%CI, and by genotype (compared to a baseline of the homozygote for the common allele)).

  Chromosomal Region   Postulated gene   SNP          MAF    \% of variation in log nevus count explained by SNP   \% of variation in pigmentation explained by SNP   Per-allele OR (95% CI) for risk of melanoma   OR (95% CI) for risk of melanoma with one copy of Minor allele   OR (95% CI) for risk of melanoma with two copies of Minor allele                       
  -------------------- ----------------- ------------ ------ ----------------------------------------------------- -------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------ ------------------- --------------------
  2q33-q34             CASP8             rs13016963   0.33   0.21                                                  0.083[\*](#TFN2){ref-type="table-fn"}              0.05                                          0.33                                                             1.25 (1.07, 1.46)                                                  1.26 (1.01, 1.56)   1.56 (1.11, 2.18)
  5p15.33              TERT/CLMPT1L      rs401681     0.46   0.50                                                  **0.0070**                                         0.13                                          0.11                                                             1.08 (0.93, 1.25)                                                  1.15 (0.90, 1.47)   1.15 (0.85, 1.55)
  5p13.2               SLC45A2           rs16891982   0.03   0.02                                                  0.62                                               1.33                                          **1.9 × 10^−6^**                                                 0.72 (0.44, 1.18)                                                  0.78 (0.47, 1.30)   NA
  6p25-p23             IRF4              rs12203592   0.24   0.21                                                  0.084                                              2.76                                          **5.6 × 10^−12^**                                                0.80 (0.67, 0.95)                                                  0.72 (0.58, 0.91)   0.81 (0.49, 1.35)
  9p21                 CDKN2A/MTAP       rs7023329    0.49   0.29                                                  **0.047**                                          0.02                                          0.55                                                             0.86 (0.73, 1.00)                                                  0.62 (0.47, 0.82)   0.73 (0.53, 1.01)
  11q14-q21            TYR               rs1393350    0.27   0.00                                                  0.95                                               1.07                                          **2.0 × 10^−5^**                                                 1.34 (1.14, 1.58)                                                  1.19 (0.96, 1.49)   2.12 (1.41, 3.19)
  11q22-q23            ATM               rs1801516    0.14   0.07                                                  0.33                                               0.00                                          0.95                                                             0.88 (0.71, 1.09)                                                  0.93 (0.73, 1.19)   0.59 (0.29, 1.21)
  16q24.3              MC1R              rs258322     0.10   0.00                                                  0.81                                               4.00                                          **9.0 × 10^−17^**                                                1.83 (1.44, 2.32)                                                  1.71 (1.33, 2.22)   7.14 (1.70, 29.98)
  20q11.2-q12          ASIP              rs4911442    0.13   0.07                                                  0.34                                               0.93                                          **8.2 × 10^−5^**                                                 1.35 (1.08, 1.68)                                                  1.32 (1.03, 1.69)   2.06 (0.85, 5.00)
  21q22.3              MX2               rs45430      0.38   0.00                                                  0.80                                               0.05                                          0.32                                                             0.90 (0.77, 1.05)                                                  0.97 (0.77, 1.22)   0.77 (0.56, 1.07)
  22q13.1              PLA2G6            rs6001027    0.37   0.39                                                  **0.018**                                          0.12                                          0.16                                                             0.78 (0.66, 0.91)                                                  0.79 (0.63, 0.90)   0.60 (0.42, 0.84)
                       **TOTAL**                             2.33                                                                                                     9.83                                                                                                                                                                                                  

p = 0.004 for controls only
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